Polyneuropathy due to other toxic agents

G6_TOXICPOLY

No definition available.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — G62.2 Hospital discharge: ICD-9 — 3577A Cause of death: ICD-10 — G62.2 Cause of death: ICD-9 — 3577A 2 out of 7 registries used, show all original rules.	28
4. Check minimum number of events None	28
5. Include endpoints None	28
6. Filter based on genotype QC (FinnGen only)	28

Control definitions (FinnGen only)

Control exclude: G6_POLYNEU

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: G62
Name in latin: Polyneuropathia toxica

NAME	G6_TOXICPOLY
CONTROL_EXCLUDE	G6_POLYNEU
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	G622
HD_ICD_9	3577A
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	G622
COD_ICD_9	3577A
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Polyneuropathy due to other toxic agents based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	291	111	177
Only index persons	232	96	136
Unadjusted period prevalence (%)
Whole population	0.00	0.00	0.00
Only index persons	0.00	0.00	0.01
Median age at first event (years)
Whole population	59.23	59.76	58.87
Only index persons	59.10	59.84	58.58

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	28	10	18
Unadjusted period prevalence (%)	0.01	0.00	0.01
Median age at first event (years)	60.71	57.85	62.29

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

unit

cases

controls

-log₁₀(p)

N cases

N controls

(3000494) Fungus identified in Specimen by Culture

5.67

4.10

2.8

1.3

—

(42870588) Differential panel, method unspecified - Blood

4.50

3.70

11.7

5.8

—

(3004588) Protein electrophoresis panel - Serum or Plasma

6.98

3.48

4.4

1.6

—

(3009445) Proteinase 3 Ab [Units/volume] in Serum

7.27

2.85

1.7

1.1

—

(3026782) Osmolality of Urine

3.82

2.80

3.8

2.8

mosm/kgh2o

481.3

536.9

0.42

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

4.54

2.32

1.7

1.6

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

4.54

2.32

1.9

1.4

—

(3023368) Bacteria identified in Blood by Culture

3.18

2.20

9.5

4.4

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

4.46

2.06

3.8

1.2

—

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

5.27

2.03

4.0

1.8

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

3.19

1.96

4.1

1.5

—

(3013826) Glucose [Moles/volume] in Serum or Plasma

142

2.91

1.78

9.4

6.5

mmol/l

6.6

7.0

0.30

134

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

3.24

1.71

1.7

1.6

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

2.65

1.66

5.6

3.0

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

3.56

1.50

5.2

3.1

—

(3007853) Bacteria identified in Skin by Aerobe culture

2.88

1.44

3.5

1.5

—

(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma

161

2.70

1.38

15.9

7.6

u/l

85.5

78.9

0.31

152

(36304419) Bacteria [Presence] in Urine

2.38

1.30

5.3

2.9

—

(3009542) Hematocrit [Volume Fraction] of Blood

179

2.59

1.21

58.2

17.5

33.5

39.9

1.13

130

(3042936) Bacteria identified in Isolate by Culture

2.67

1.21

3.9

1.6

—

(4010399)

2.81

1.20

1.6

1.1

—

(3019060) Gas panel - Arterial blood

2.81

1.20

14.4

2.7

—

(3019198) Lymphocytes [#/volume] in Blood

105

2.22

1.17

17.5

6.0

e9/l

1.9

1.7

0.17

(3044640) Blood type and Crossmatch panel - Blood

2.21

1.11

3.0

2.4

—

(3026008) Bacteria identified in Urine by Culture

2.18

1.05

11.5

2.6

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

2.45

0.98

4.0

1.4

—

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

2.09

0.98

3.3

4.6

ng/l

3293.8

1129.9

0.39

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

2.35

0.96

5.2

1.4

—

(3037467) Urinalysis macro (dipstick) panel - Urine

154

2.04

0.95

14.5

3.8

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

2.18

0.90

2.3

1.9

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

2.11

0.87

11.5

9.1

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

108

1.84

0.75

9.1

3.8

—

(3012544) pH of Venous blood

1.88

0.67

36.8

4.2

—

(3021447) Carbon dioxide [Partial pressure] in Venous blood

1.88

0.67

36.8

4.2

kpa

5.7

5.9

—

(40768804) Tissue Pathology biopsy report

1.75

0.63

1.8

1.9

—

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

1.73

0.59

1.2

1.1

—

0.5

—

(40760892) CBC W Ordered Manual Differential panel - Blood

1.69

0.54

7.9

4.9

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

1.60

0.48

2.4

2.3

—

(40758558) Short blood count panel - Blood

1.60

0.48

17.6

7.4

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

121

1.52

0.40

3.6

2.9

—

(3041096) Erythrocytes [Presence] in Urine by Automated

1.40

0.32

9.1

2.8

—

(3013512) EKG study

1.38

0.32

7.1

4.4

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

1.38

0.25

1.2

—

3.1

—

(1002224) Polysomnography panel

0.00

0.22

0.0

1.0

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

0.00

0.22

0.0

1.4

—

(3019832) Treponema pallidum Ab [Presence] in Serum

0.00

0.21

0.0

2.0

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

1.33

0.21

3.4

3.3

—

(1761868) Lipid panel - Serum or Plasma

0.68

0.19

5.2

3.4

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

1.10

0.01

8.7

3.2

—

(3044889) 12 lead EKG panel

154

0.94

0.00

7.1

4.0

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

5.4

—

307.2

—

(3045414) Leukocytes [Presence] in Urine

0.00

0.0

2.4

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.0

4.1

—

21.3

—

(3044242) Glucose [Moles/volume] in Arterial blood

0.00

0.0

2.0

—

(3006184) Hemoglobin [Mass/volume] in Capillary blood

0.00

0.0

3.4

—

135.2

—

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

3.0

—

(3014702) Chromogranin A [Moles/volume] in Serum or Plasma

0.00

0.0

1.0

—

3.6

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

0.00

0.0

1.3

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.0

1.3

—

(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay

0.00

0.0

1.0

—

(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma

0.00

0.0

1.6

—

(3012110) Lysozyme [Mass/volume] in Serum or Plasma

0.00

0.0

1.2

—

9.9

—

(3012413) Glucose [Moles/volume] in Serum or Plasma --2 hours post meal

0.00

0.0

1.0

—

(3008898) HLA-B27 [Presence]

0.00

0.0

1.0

—

(42529201) Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

5.2

—

222.0

—

(3020564) Creatinine [Moles/volume] in Serum or Plasma

229

1.02

0.00

50.2

17.6

umol/l

89.7

78.9

0.36

229

(3009508) Creatinine [Moles/volume] in Urine

1.04

0.00

7.0

2.9

mmol/l

4.5

7.7

—

(3001019) Free T4 and TSH panel - Serum or Plasma

0.00

0.0

1.4

—

(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay

0.00

0.0

1.0

—

(3024928) Oxygen saturation in Venous blood

0.00

0.0

6.0

—

Mortality – FinRegistry

↥

Association

Association between endpoint G6_TOXICPOLY and mortality.

Females

No data

Males

Parameter	HR [95% CI]	p-value
G6_TOXICPOLY	3.703 [2.35, 5.84]	< 0.001
Birth year	0.98 [0.97, 0.99]	< 0.001

During the follow-up period (1.1.1998 — 31.12.2019), 67 out of 137 males with G6_TOXICPOLY died.

Mortality risk

Mortality risk for people of age

years, who have G6_TOXICPOLY.

N-year risk	Females	Males
1	No data	0.653%
5	No data	3.499%
10	No data	8.612%
15	No data	15.71%
20	No data	24.986%

Relationships between endpoints

↥

Index endpoint: G6_TOXICPOLY – Polyneuropathy due to other toxic agents

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Polyneuropathy due to other toxic agents

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints